LncRNA-p21 inhibited the proliferation of osteosarcoma cells via the miR-130b/PTEN/AKT signaling pathway - 31/12/17
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 7 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | The expression of long non-coding RNA-p21 (lncRNA-p21) is downregulated in osteosarcoma tissue. |
• | LncRNA-p21 is a potent repressor of AKT activity in osteosarcoma cell lines. |
• | The lncRNA-p21/miR-130b/PTEN axis is responsible for AKT suppression and subsequent cell proliferation inhibition. |
Abstract |
Osteosarcoma (OS) is the most common type of malignant bone tumor in children and adolescents. However, the molecular mechanism underlying OS development is unclear. Here, we investigated the contribution of lncRNA-p21, a novel long non-coding RNA, on OS cell proliferation. Our results demonstrated that the expression of lncRNA-p21 was repressed in OS tissue. Growth curves and the cell colony formation assay showed that lncRNA-p21 significantly inhibited the proliferation of OS cell lines. In addition, the expression of lncRNA-p21 increased the protein levels of proliferation markers, such as Ki-67 and cyclin D1. Subsequently, lncRNA-p21 overexpression up-regulated the protein level of phosphatase and tensin homolog deleted on chromosome ten (PTEN), a well-known inhibitor of AKT signaling. Moreover, our gain and loss function assay showed that the promotion of PTEN by lncRNA-p21 was mediated by miR-130b, an oncogene overexpressed in OS tissue. Our findings may provide a novel lncRNA-targeted therapy for patients with OS.
Le texte complet de cet article est disponible en PDF.Keywords : LncRNA-p21, PTEN, AKT, Osteosarcoma, Proliferation
Plan
Vol 97
P. 911-918 - janvier 2018 Retour au numéro
Article précédent
- Lipoxin A4 protects against spinal cord injury via regulating Akt/nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 signaling
- Tan Lu, Xuejian Wu, Na Wei, Xiaotan Liu, Yingfeng Zhou, Chunfeng Shang, Yongzhuang Duan, Yuzhen Dong
- Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors
- Samir Rabadiya, Shradhha Bhadada, Ashvin Dudhrejiya, Devendra Vaishnav, Bhoomika Patel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?